Yiling subsidiary gains approval for key Alzheimer's drug ingredient

Shijiazhuang Yiling Pharmaceutical Co. announced its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical, received National Medical Products Administration approval for "Memantine Hydrochloride" as a chemical raw material. This allows Wanyang Hengshui to sell the active pharmaceutical ingredient (API) in the domestic market, enriching its product line and expanding its business scope.

Memantine Hydrochloride treats moderate to severe Alzheimer's type dementia. China has approximately 16.9 million dementia patients, a number expected to rise with an aging population.

The Chinese anti-dementia market was valued at 1.56 billion yuan, with Memantine being a first-line treatment, holding a 22% market share. Projections indicate the Chinese Memantine Hydrochloride market will reach 340 million yuan in 2025, growing by 11% year-on-year, with sales volume increasing by 19%. This approval provides Wanyang Hengshui an opportunity to increase its market share.